COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2023
23/01/2024
Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2023 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2023
23/01/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2023 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]
Veteran’s Health Administration Joins Pulse by NABP
23/01/2024
MOUNT PROSPECT, IL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Veteran’s Health Administration (VHA) has joined Pulse by NABP™, the National Association of Boards of Pharmacy ® ’s (NABP ® ’s) new digital platform that will [...]
Talent Agency IT Model Management Selects CosmetiCare MedSpa and Surgery Center as Their Face, Body and Skin Care Preferred Provider
23/01/2024
CORONA DEL MAR, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- It Model Management, one of the leading print and television talent agencies with locations in Southern California and Austin and Dallas, Texas has selected [...]
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
23/01/2024
Results clearly demonstrate the business’s ability to reach breakeven in the near future NEW HAVEN, Conn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces [...]
Visory Health Announces The Kroger Company As Preferred Pharmacy
23/01/2024
The prescription discount card has helped customers save over $5 billion on prescriptions at over 35,000 pharmacies nationwide ORLANDO, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Visory Health , a women-led, patient-first [...]
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
23/01/2024
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla ® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to [...]
Baylor Genetics Chief Medical Officer Christine Eng, M.D., Shares Sequencing Approaches for Undiagnosed Patients at Precision Medicine World Conference 2024
23/01/2024
Showcase Presentation to Include Case Examples from NIH’s Undiagnosed Diseases Network (UDN), Demonstrating Diagnostic Impact of Whole Genome Sequencing on Medical Care HOUSTON, Texas, Jan. 23, 2024 (GLOBE NEWSWIRE) -- [...]
HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT
23/01/2024
Category I CPT code for Fractional Flow Reserve derived from Computed Tomography will provide broader access to HeartFlow’s AI-powered technology, a standard of care for evaluating and treating coronary artery disease [...]
Vivtex Enters Research Collaboration with Astellas Pharma
23/01/2024
Cambridge, MA, USA and Zurich, Switzerland – 23 rd January 2024 . Vivtex Corporation (“Vivtex” or “the Company”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, [...]
Alberta Cancer Foundation announces initial investment of its novel philanthropic Breakthrough Fund to support early-stage cancer research
23/01/2024
Entos Pharmaceuticals and 48Hour Discovery named as first recipients of Breakthrough Fund EDMONTON, Alberta, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is thrilled to announce that Entos [...]
Industry-Recognized Technology Leader Joins DLH as Strategic Advisor
23/01/2024
ATLANTA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, science research and development, and systems [...]
Privia Health to Report Fourth Quarter and Full-Year 2023 Results on Tuesday, February 27
23/01/2024
ARLINGTON, Va., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to release financial results for its fourth quarter and full year ended December 31, 2023 before [...]
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
23/01/2024
- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys’ earlier FemBloc study - - FemBloc is being developed as a first-of-its- [...]
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
23/01/2024
CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer. “We are thrilled to welcome Dr. [...]
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
23/01/2024
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
23/01/2024
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. [...]
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
23/01/2024
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately [...]
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
23/01/2024
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with [...]

Pages